Overview
Yellow fever is an acute viral hemorrhagic disease caused by yellow fever virus (YFV), a mosquito-borne flavivirus. It is endemic across tropical Africa and Latin America, causing an estimated 200,000 cases and 30,000 deaths annually — of which 90% occur in Africa. One of the oldest vaccines in human history (17D, developed 1937) provides lifelong protection with a single dose. Yet yellow fever kills tens of thousands of people every year. This is not a science failure. It is a delivery, coverage, and political will failure.
Global Burden (2025 est.)
- ~200,000 cases annually (estimated)
- ~30,000 deaths per year
- 90% of cases in sub-Saharan Africa
- 47 endemic countries (34 Africa, 13 Americas)
- 900 million people at risk
Pathogen
- Family: Flaviviridae
- Genus: Orthoflavivirus
- Single serotype — one strain, universal immunity
- ssRNA+ genome, ~10.9 kb
- 5 genotypes (West Africa I/II, East/Central Africa, Angola, South America I/II)
Primary Vectors
- Aedes aegypti — urban cycle
- Aedes africanus — sylvatic Africa
- Haemagogus janthinomys — sylvatic Americas
- Haemagogus leucocelaenus — sylvatic Americas
- Sabethes chloropterus — forest canopy Americas
The Paradox
- 17D vaccine: single dose, lifelong protection
- One of the most effective vaccines ever made
- Available since 1937
- Cost: ~$1 per dose in endemic countries
- Sylvatic reservoir makes eradication impossible
- Outbreaks persist due to coverage gaps alone
Severe underreporting: WHO estimates true case counts are 10–250 times higher than officially reported figures. Yellow fever surveillance is weak in most endemic countries. The 200,000 case estimate is a modeled figure. The actual burden is unknown.
Taxonomy and Classification
Yellow fever virus is the type species of the genus Orthoflavivirus (formerly Flavivirus) — the genus name itself derives from the Latin flavus (yellow), named for the jaundice that characterises severe yellow fever disease. The 2023 ICTV reclassification renamed the genus from Flavivirus to Orthoflavivirus, placing YFV alongside dengue, Zika, West Nile, and Japanese encephalitis viruses.
Relationship to Other Flaviviruses
Dengue Virus (DENV 1–4)
Four serotypes vs. YFV's single serotype. Shares Aedes aegypti as primary urban vector. No cross-protective immunity between YFV and DENV. Both cause hemorrhagic disease via distinct pathological mechanisms.
Zika Virus (ZIKV)
Same genus, same primary vector (Ae. aegypti). Zika serological cross-reactivity with YFV antibodies complicates diagnostics in co-endemic areas. Zika is teratogenic; YFV is not known to be.
West Nile Virus (WNV)
Bird-amplified flavivirus; Culex vectors. No primate sylvatic reservoir like YFV. Serological cross-reactivity with YFV in travellers with 17D vaccination history — a diagnostic consideration.
Japanese Encephalitis Virus (JEV)
Pig-amplified, Culex-transmitted. Causes encephalitis, not hemorrhagic fever. The JEV vaccine (SA14-14-2) is a live-attenuated virus developed on the same platform principles as 17D — YFV's vaccine legacy influenced the whole field.
Transmission Cycles
Yellow fever circulates in three distinct transmission cycles, each involving different mosquito vectors and vertebrate hosts. The sylvatic cycle is the reservoir impossible to eliminate. Urban transmission is entirely preventable with vaccination.
Genome and Genetic Data
Yellow fever virus has a single-stranded positive-sense RNA genome of approximately 10,862 nucleotides — the same basic flavivirus architecture shared with dengue and Zika. A single open reading frame encodes a polyprotein that is cleaved co- and post-translationally into three structural and seven non-structural proteins. Unlike dengue (4 serotypes) and Zika, YFV has a single serotype — meaning infection or vaccination with any strain confers universal protection.
Figure 1. YFV genome map (~10.9 kb): structural proteins (C, prM, E — red/orange) and non-structural proteins NS1–NS5 (blue/teal/purple). Architecture identical to dengue. NS5 encodes the RNA-dependent RNA polymerase — the primary drug target. The single serotype of YFV is determined by the envelope (E) protein.
Serotypes: 1 (single serotype — universal cross-protection)
Genotypes: 5 — West Africa I, West Africa II, East/Central Africa, Angola clade, South America I, South America II
Reference strain: Asibi (Ghana, 1927) · GenBank:
AY64058917D vaccine strain: 17D-204 · GenBank:
X15062 · derived from Asibi by 176 passagesProtein-coding regions: C (capsid) · prM/M (membrane) · E (envelope) · NS1–NS5
Protein Functions and Drug Targets
| Protein | Type | Function | Drug / Vaccine Target? |
|---|---|---|---|
| C (Capsid) | Structural | Packages genomic RNA | Research |
| prM/M (Membrane) | Structural | Chaperones E protein; cleaved on maturation | No |
| E (Envelope) | Structural | Cell attachment, membrane fusion, major antigen; determines serotype | Vaccine (17D targets E) |
| NS1 | Non-structural | RNA replication cofactor; secreted — diagnostic antigen and immunopathology mediator | Diagnostic; Research |
| NS2A | Non-structural | Membrane rearrangement; innate immune evasion | No |
| NS2B | Non-structural | NS3 serine protease cofactor | Research |
| NS3 | Non-structural | Serine protease + helicase; essential for polyprotein processing and RNA replication | Active — protease inhibitors |
| NS4A | Non-structural | Membrane curvature; replication complex anchor | Research |
| NS4B | Non-structural | Replication complex scaffold; interferon antagonist | Research |
| NS5 | Non-structural | RNA-dependent RNA polymerase (RdRp) + N7 methyltransferase; essential for replication | Active — nucleoside analogs |
The Single-Serotype Advantage
YFV's single serotype is its most important epidemiological feature. Unlike dengue — where four serotypes create the antibody-dependent enhancement (ADE) problem that has frustrated vaccine development for decades — a person infected with any YFV strain, or vaccinated with any 17D-derived vaccine, is protected against all circulating YFV globally. This is why 17D works so cleanly. It is also why, unlike dengue, yellow fever vaccine development required only one attempt to get right.
Sylvatic (Jungle) Cycle — Africa
Hosts: Non-human primates (monkeys, baboons) — the amplifying reservoir. Humans are incidental dead-end hosts.
Vectors: Aedes africanus (canopy), Ae. luteocephalus, Ae. furcifer, other forest Aedes spp.
Risk: Unvaccinated forest workers, hunters, people living near forest margins. Sporadic, unpredictable.
Sylvatic (Jungle) Cycle — Americas
Hosts: Howler monkeys, spider monkeys, other New World primates. Monkey die-offs are sentinel events for human risk.
Vectors: Haemagogus janthinomys, Haemagogus leucocelaenus, Sabethes chloropterus — canopy-dwelling species.
Risk: Forest workers, eco-tourism, agricultural expansion into forest margins. Brazil 2017–2018 epizootic killed thousands of monkeys.
Intermediate (Savannah) Cycle — Africa Only
Hosts: Both humans and non-human primates. Semi-domestic Aedes spp. bridging forest and village.
Vectors: Ae. furcifer, Ae. taylori, Ae. luteocephalus.
Pattern: Most African yellow fever outbreaks originate here — human cases spillover from primate-to-human transmission in savannah-forest interface villages.
Urban Cycle
Hosts: Humans only — human-to-mosquito-to-human. No primate reservoir required.
Vector: Aedes aegypti exclusively — the highly domesticated, urban container-breeder.
Risk: Explosive epidemic potential in unvaccinated urban populations. Last major urban outbreak: Angola/DRC 2015–2016 (~7,000 suspected cases). Urban YF is the nightmare scenario — it has not returned to large cities since the 20th century largely because of historical vaccination campaigns.
Urban re-emergence threat: Aedes aegypti is present at high density in major African and South American cities with chronically low yellow fever vaccination coverage. A single sylvatic spillover case entering an unvaccinated urban population with abundant Ae. aegypti is sufficient to trigger exponential urban transmission. Lagos, Kinshasa, and Luanda are considered high-risk cities.
Vectors
Yellow fever vectors span two mosquito genera — Aedes and Haemagogus — with distinct ecologies, bite patterns, and geographic distributions. The urban vector (Ae. aegypti) is the same species that transmits dengue, Zika, and chikungunya, making yellow fever urban risk a direct function of Ae. aegypti control — or the lack of it.
Cycle: Urban yellow fever (global)
The dominant urban vector worldwide. Highly domesticated, breeds in artificial containers. Day-biting; peak activity at dawn and dusk. Responsible for all urban yellow fever transmission and the explosive epidemic potential in cities.
- Distribution: tropical and subtropical worldwide
- Also primary vector for dengue, Zika, chikungunya
- Intrinsic incubation period: ~9–12 days at 28°C
Cycle: Sylvatic Africa (primary forest vector)
Canopy-dwelling forest species. Primary vector sustaining the sylvatic cycle in East and Central Africa. Feeds on non-human primates in the forest canopy; descends to forest floor.
- Distribution: tropical Africa
- Low vector competence for urban amplification
- Important for maintenance of primate reservoir
Cycle: Sylvatic Americas (primary)
The dominant sylvatic vector in South America. Canopy specialist; feeds on monkeys and humans who enter the forest. Responsible for most sylvatic spillover to humans in Brazil.
- Distribution: Amazonia, Atlantic Forest, Brazil, Trinidad
- Breeds in tree holes and bromeliads in forest canopy
- Highly efficient YFV vector; long extrinsic incubation period (~12–14 days)
Cycle: Sylvatic Americas (secondary)
Co-vector with Hg. janthinomys in the Atlantic Forest region. Important in southern Brazil outbreaks, particularly the 2017–2018 epizootic that reached the outskirts of São Paulo and Rio de Janeiro.
- Distribution: Atlantic Forest zone, Argentina, Paraguay
- More generalist feeding; higher human contact rate than Hg. janthinomys in some habitats
Cycle: Sylvatic Americas (tertiary)
Forest canopy species; striking iridescent appearance. Less important epidemiologically than Haemagogus but contributes to sylvatic maintenance. Breeds in water-filled tree holes and bromeliads.
- Distribution: Central America through northern South America
- Competent YFV vector in laboratory; field importance varies by region
Cycle: Intermediate/savannah Africa
Semi-domestic African species bridging forest and village environments. The primary vectors in the intermediate (savannah) transmission cycle responsible for most African outbreaks.
- Distribution: West and Central African savannah zone
- Both primate-feeding and human-feeding
- Key link between sylvatic reservoir and human populations
Clinical Disease
Yellow fever presents as a spectrum from mild febrile illness to a fulminant hemorrhagic syndrome with 20–50% case fatality. The classic severe form — with its biphasic presentation, jaundice, hemorrhage, and renal failure — is the disease that carved its name into history. Most infections, however, are mild or subclinical.
Phase 1 — Infection (Acute)
Onset: 3–6 days after infective bite
Duration: 3–4 days
Sudden onset fever, chills, severe headache, back pain, myalgia, nausea, vomiting. Relative bradycardia despite fever (Faget's sign — a classic YF clinical finding). High-level viraemia. Most patients recover completely at this stage.
~85% of all cases resolve here. Lifelong immunity follows.
Phase 2 — Remission
Duration: Hours to 24 hours
Brief period of apparent improvement. Fever subsides. Patient appears to be recovering. This remission is deceptive — approximately 15% will progress to the toxic phase within hours.
The return of fever after remission is the clinical warning sign of impending toxic phase.
Phase 3 — Toxic Phase
Duration: Days to 1–2 weeks
Case fatality: 20–50% of those who reach this phase
Return of high fever with rapid multi-organ involvement:
Jaundice (icterus): The defining sign — hepatocellular injury causes bilirubin accumulation. Gives the disease its name.
Hemorrhagic manifestations: Bleeding from gums, nose, GI tract. Haematemesis (black vomit — vómito negro) — blood digested in stomach. Petechiae, ecchymoses.
Renal failure: Oliguria, proteinuria, rising creatinine.
Cardiovascular: Hypotension, arrhythmia, shock.
Neurological: Delirium, seizures, coma in terminal cases.
Death typically occurs 7–10 days after onset from multi-organ failure. Survivors recover completely with no chronic sequelae.
| Finding | Acute Phase | Toxic Phase | Clinical Significance |
|---|---|---|---|
| Leucopenia | Present | Persistent | Characteristic early finding; helps distinguish from bacterial infection |
| Transaminases (AST/ALT) | Mildly elevated | Markedly elevated (AST > ALT) | Hepatic injury; AST>ALT pattern typical of YF hepatitis |
| Bilirubin | Normal | Elevated — jaundice | Hepatocellular + hemolytic; jaundice = toxic phase entry |
| Creatinine | Normal | Rising | Renal tubular necrosis; oliguria a poor prognostic sign |
| Coagulation (PT/INR) | Normal | Prolonged | Hepatic coagulopathy; DIC in severe cases |
| Viraemia | High | Declining (antibody clearance) | PCR/NS1 antigen positive in acute phase; serological window in toxic phase |
| Proteinuria | Absent | Present — often heavy | Renal involvement; correlates with severity |
Faget's Sign: Relative bradycardia in the presence of high fever — pulse rate lower than expected for the degree of fever. A classic clinical sign in yellow fever, also seen in typhoid. Its presence in a febrile patient returning from an endemic area should prompt immediate yellow fever testing.
Treatment and Clinical Management
There is no specific approved antiviral treatment for yellow fever. Management is entirely supportive. This makes the existence of a highly effective vaccine not merely convenient but medically essential — there is nothing to fall back on once severe disease develops.
No approved antiviral: As of 2025, no specific antiviral drug is approved or recommended for yellow fever treatment. Ribavirin, interferon, and several nucleoside analogs have been evaluated — none with sufficient clinical efficacy to alter management. Supportive care is the standard of care.
Supportive Care
Fever and Pain Management
RecommendedParacetamol (Acetaminophen) — first-line for fever and myalgia.
Aspirin and NSAIDs strictly contraindicated — antiplatelet effects catastrophic in hemorrhagic phase thrombocytopenia and coagulopathy.
Fluid and Hemodynamic Management
RecommendedIV crystalloid fluids for dehydration and shock. Careful titration essential — hepatic and renal failure alter fluid handling significantly. Vasopressors for refractory hypotension in ICU setting.
Renal Replacement Therapy
ICU — Selective UseHaemodialysis or CRRT for severe acute kidney injury with oliguria/anuria. Renal failure is a major driver of mortality in toxic phase. Dialysis support in equipped centres improves survival.
Coagulopathy Management
Selective UseFresh frozen plasma, vitamin K for documented coagulopathy with active bleeding. Platelet transfusion for severe thrombocytopenia with hemorrhage. Avoid empirical use — DIC management is complex in hepatic failure context.
Contraindications
Aspirin and all NSAIDs
Strictly ContraindicatedAntiplatelet effects combined with YFV-induced thrombocytopenia and coagulopathy dramatically increase hemorrhagic risk. Aspirin also risks Reye syndrome in children. Absolutely contraindicated throughout illness.
Intramuscular Injections
Avoid in Hemorrhagic PhaseRisk of hematoma formation at injection sites in coagulopathic patients. Use intravenous routes; if IM unavoidable, apply firm pressure.
Ribavirin
Not Recommended — No EfficacyEvaluated in case series and animal models — no demonstrated benefit against YFV in vivo. Not standard of care. May be considered compassionate use but evidence is absent.
The 17D Vaccine — History and Biology
The yellow fever 17D vaccine is one of the most successful vaccines ever developed — arguably the most successful live attenuated viral vaccine in history. A single dose confers lifelong immunity in >99% of recipients. It is cheap, thermostable relative to many vaccines, and has been administered to over 600 million people. That yellow fever still kills 30,000 people per year despite this tool existing since 1937 is one of the starkest indictments of global health equity in existence.
Development History
Max Theiler (Rockefeller Institute) attenuated the wild-type Asibi strain (Ghana, 1927) by serial passage in mouse brain and chick embryo tissue — 176 passages total. The 17D strain emerged around passage 89. Theiler received the Nobel Prize in Physiology or Medicine in 1951 — the only Nobel awarded for a tropical disease vaccine.
Mechanism of Attenuation
The 17D genome differs from wild-type Asibi at 68 nucleotide positions (32 amino acid changes). Key mutations in the E protein reduce neurotropism and viscerotropism while maintaining immunogenicity. The attenuated virus replicates to low levels, producing robust humoral and cellular immune responses without causing disease in immunocompetent individuals.
Efficacy and Duration
Seroconversion in >99% of immunocompetent recipients. Neutralizing antibodies detectable within 10–14 days. WHO revised guidance in 2013: a single dose confers lifelong protection — booster doses are no longer recommended for most travellers (exceptions: pregnant women vaccinated during pregnancy, HIV-infected individuals, infants vaccinated before 9 months).
Current Licensed Vaccines
- YF-VAX (Sanofi Pasteur) — USA, Canada
- Stamaril (Sanofi Pasteur) — Europe, international
- Bio-Manguinhos 17DD (Fiocruz, Brazil) — primary supply for endemic countries; WHO prequalified
- ARILVAX — UK (discontinued)
- All are 17D-derived sub-strains (17D-204 or 17DD)
Vaccine Safety — Rare Serious Adverse Events
Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD)
Rate: ~0.4/100,000Rare but potentially fatal multi-organ failure clinically resembling wild-type yellow fever. Risk highest in adults >60 years and those with thymus disorders. Mechanism not fully understood — may involve uncontrolled vaccine virus replication. Case fatality ~65% when it occurs. Contraindications must be strictly observed.
Yellow Fever Vaccine-Associated Neurotropic Disease (YEL-AND)
Rate: ~0.8/100,000Meningoencephalitis or Guillain-Barré-like syndrome. More common in infants <6 months (contraindicated) and immunocompromised individuals. Usually self-limiting. Rare fatalities reported. Infants <6 months must not receive 17D.
Contraindications
AbsoluteInfants <6 months (YEL-AND risk). Severe immunodeficiency (HIV CD4 <200, chemotherapy, high-dose corticosteroids). Thymus disorders (thymoma, thymectomy). Severe egg allergy. Prior anaphylaxis to vaccine components.
Precautions
Relative ContraindicationAge ≥60 years — increased YEL-AVD risk; risk-benefit assessment required. Pregnancy — avoid unless travel to endemic area unavoidable; theoretical teratogenic risk. Breastfeeding — case reports of vaccine-strain transmission to infant via breast milk.
Fractional dosing: During the 2016 Angola/DRC outbreak, vaccine supplies ran critically short. WHO authorized fractional dosing (1/5 standard dose) for emergency use — demonstrated to provide protective immunity for at least 12 months in adults. A pragmatic tool for outbreak response when supply is constrained.
Outbreak History and Key Events
Yellow fever has shaped the history of the Americas and Africa in ways few other infectious diseases have matched — it killed soldiers, ended wars, deterred colonization, and drove some of the earliest systematic public health interventions in human history. The discovery of mosquito transmission by Walter Reed and Carlos Finlay (1900–1901) was a turning point in the history of medicine.
Postulated Path to Elimination
Yellow fever cannot be eradicated — the sylvatic cycle in non-human primates is an ineradicable reservoir. The realistic goal is elimination of human disease: universal vaccination coverage preventing sylvatic spillover from becoming human cases, and preventing urban amplification entirely. This goal is scientifically straightforward. The obstacles are logistical, financial, and political.
Integrated Yellow Fever Elimination Framework
Universal Routine Childhood Immunization
Yellow fever vaccine must be integrated into national Expanded Programme on Immunization (EPI) schedules in all 47 endemic countries. Given at 9 months alongside measles vaccine. Coverage must exceed 80% nationally and reach 100% in high-risk districts. This is the single most impactful intervention.
Preventive Mass Vaccination Campaigns
One-time mass campaigns targeting all age groups in unvaccinated or under-vaccinated populations. The EYE Strategy has targeted 40 countries for preventive campaigns. Gavi funding covers vaccine procurement for the poorest nations.
Emergency Outbreak Response Capacity
Stockpiled global emergency vaccine reserve (International Coordinating Group stockpile) with fractional-dose authorization for rapid large-scale response. Response within 48 hours of confirmed outbreak. Stockpile minimum: 6 million doses maintained at all times.
Aedes aegypti Vector Control in Cities
Urban yellow fever is entirely dependent on Ae. aegypti. Integrated vector management in high-risk cities — source reduction, larviciding, Wolbachia deployment (tested against dengue; applicable to YFV urban cycle) — reduces amplification risk. Not a substitute for vaccination, but a critical second line.
Primate Sentinel Surveillance
Non-human primate die-offs are early warning signals. Systematic monkey mortality surveillance in endemic forest zones, linked to rapid human vaccination response, can interrupt spillover before urban amplification. Brazil has demonstrated this model.
Vaccine Supply Security
The 2016 Angola/DRC outbreak demonstrated that global stockpiles can be exhausted by a single large outbreak. Manufacturing capacity — currently dominated by Fiocruz (Brazil) and Sanofi — must be diversified. Technology transfer to African manufacturers is a stated EYE Strategy goal and a sovereignty imperative.
Scientific Assessment: Yellow fever elimination from human populations is achievable. The vaccine works. The obstacle is coverage — specifically the chronic failure to reach routine childhood immunization targets in the 47 endemic countries, and the political and financial neglect of disease surveillance infrastructure. Every yellow fever death in 2025 is a preventable death. The 17D vaccine has existed for 88 years. This is not a science problem. It never was.
Sources and References
All information drawn from government agencies, international health organizations, and peer-reviewed scientific literature.
Government and Intergovernmental Organizations
- World Health Organization (WHO). Yellow Fever — Fact Sheet. who.int
- WHO. Eliminate Yellow Fever Epidemics (EYE) Strategy 2017–2026. who.int
- U.S. Centers for Disease Control & Prevention (CDC). Yellow Fever — Travelers' Health. cdc.gov
- CDC. Yellow Fever Vaccine Information Statement. cdc.gov
- PAHO/WHO. Yellow Fever — Regional Information. paho.org
- ECDC. Yellow Fever — Disease Information. ecdc.europa.eu
- NCBI / NIH. Yellow fever virus Asibi genome — GenBank AY640589. ncbi.nlm.nih.gov
Peer-Reviewed Literature
- Theiler M, Smith HH. 1937. The use of yellow fever virus modified by in vitro cultivation for human immunization. Journal of Experimental Medicine 65(6):787–800.
- PMC. Yellow fever virus: molecular biology and treatment. PMC7094082. pmc.ncbi.nlm.nih.gov
- Shearer FM et al. 2018. Global yellow fever vaccination coverage from 1970 to 2016. The Lancet Infectious Diseases Pub Med